-
Member
Biotechnology AVX,ACR,AVP.......
Heres a list of biotechnology stocks currently on the ASX, some people might want to research some of the companies in the future.
ACR Acrux Ltd
AVP Acuron Ltd
AHG Advance Healthcare Group Ltd
AOS Advanced Ocular Systems Ltd
AEI Aeris Technologies Ltd
AFT AFT Corporation Ltd
AGX Agenix Ltd
ACL Alchemia Ltd
ABI Ambri Ltd
ANX Anadis Ltd
ALT Analytica Ltd
ANP Antisense Therapeutics Ltd
AOP Apollo Life Sciences Ltd
AQL Aquacarotene Ltd
ACG AtCor Medical Holdings Ltd
ACU Avantogen Ltd
AUH Australian Healthcare Technology Ltd
AVS Avastra Ltd
AVX Avexa Ltd
AVT AVT Holdings Ltd
BLT Benitec Ltd
BDM Biodiem Ltd
BLS Biolayer Coropration Ltd
BOD BioMD Ltd
BNO Bionomics Ltd
BPH BioPharmica Ltd
BPO Bioprospect Ltd
BOS Biosignal Ltd
BTA Biota Holdings Ltd
BTC Biotech Capital Ltd
BIT Biotron Ltd
BNE Bone Medical Limited
BKL Blackmores Ltd
BRC Brain Resource Company Ltd (The)
BZI BrainZ Instruments Ltd
CXD CathRx Ltd
CST Cellestis Ltd
CMQ Chemeq Ltd
CXS Chemgenex Pharmaceuticals Ltd
CIR Circadian Technologies Ltd
CCE Clinical Cell Culture Ltd
CLV Clover Corporation Ltd
COH Cochlear Ltd
CGS Cogstate Ltd
CAU Colltech Australia Ltd
CMP Compumedics Ltd
CTE Cryosite Ltd
CSL CSL Ltd
CUV Clinuvel Pharmaceuticals Ltd
CYC Cyclopharm Ltd
CYN Cygenics Ltd
CYT Cytopia Ltd
DIA Dia-B Tech Limited
EMS Eastland Medical Systems Ltd
EIF Eiffel Technologies Ltd
ELX Ellex Medical Lasers Ltd
EQX Eqitx Ltd
EGX EvoGenix Ltd
FER Fermiscan Holdings Ltd
FPH Fisher & Paykel Healthcare Corporation Ltd
GAA Genepharm Australasia Ltd
GBL Genesis Biomedical Ltd
GEN Genesis Research and Development Corporation Ltd
GTG Genetic Technologies Ltd
GIA Giaconda Ltd
HLT Healthpoint Technologies Ltd
HTW HeartWare Ltd
HTX HealthLinx Ltd
IAT IATIA Ltd
IBA IBA Health Ltd
IMI IM Medical Ltd
IML IMD Group Ltd
IMU Imugene Ltd
ICV Incitive Ltd
IDT Institute of Drug Technology Australia Ltd
ITD ITL Ltd
LBT Labtech Systems Ltd
LFE Life Therapeutics Ltd
LIP Lipa Pharmaceuticals Ltd
LCT Living Cell Technologies Ltd
KSX KarmelSonix Ltd
MYP Mayne Pharma Ltd
MAA Medec Ltd
MVP Medical Developments International Ltd
MDM Medical Monitors Ltd
MTY Medical Therapies Ltd
MGZ Medigard Ltd
MSB Mesoblast Ltd
MDV Medivac Ltd
MBP Metabolic Pharmaceuticals Ltd
NLS Narhex Life Sciences Ltd
NEU Neuren Pharmaceuticals Ltd
NDL Neuro Discovery Ltd
NAL Norwood Abbey Ltd
NRT Novogen Ltd
NSL NSL Health Ltd
OBJ OBJ Ltd
OMI Occupational & Medical Innovations Ltd
OIL Optiscan Imaging Ltd
PBO Panbio Ltd
PEP Peplin Biotech Ltd
PTD Peptech Ltd
PNO Pharmanet Group Ltd
PAA PharmAust Ltd
PXS Pharmaxis Ltd
PLT Polartechnics Ltd
PLD Portland Orthopaedics Ltd
PBT Prana Biotechnology Ltd
PBI Premier Bionics Ltd
PRR Prima Biomed Ltd
PBP Probiotec Ltd
PGL Progen Industries Ltd
POH Phosphagenics Ltd
PYC Phylogica Ltd
PCC Probiomics Ltd
PXL Proteome Systems Ltd
PSD Psivida Ltd
RMD Resmed Inc
RHT Resonance Health Ltd
RTL Ritract Ltd
RBY Rockeby Biomed Ltd
SFP Safety Medical Products Ltd
SIE Scigen Ltd
SDI SDI Ltd
SLT Select Vaccines Ltd
SIP Sigma Pharmaceuticals Ltd
SRX Sirtex Medical Ltd
SLA Solagran Ltd
SBP Solbec Pharmaceuticals Ltd
SOM SomnoMed Limited
SPL Starpharma Holdings Ltd
STI Stirling Products Ltd
SHC Sunshine Heart Inc
TIS Tissue Therapies Ltd
UNI Unitract Ltd
UBI Universal Biosensors Inc.
UCM USCOM Ltd
VCR Ventracor Ltd
VLA Viralytics Ltd
VHL Virax Holdings Ltd
VSG Visiomed Group Ltd
XBL Xceed Biotechnology Ltd
__________________________________________________ ________________
Heres one biotech company AVX that looks like a promising company. Good volumes going through of late.
Avexa is a Melbourne-based biotechnology company with a focus on research and development of drugs
for the treatment of infectious diseases, in particular diseases which have a significant unmet med
-
Here's the thread you were looking for Donnie.
Search engine sometimes misses a few threads - especially ones with no replies.
-
Member
thanks lizard.
heres what i posted on the other thread i deleted anyway.
A good rise today with good volumes going through.
Biotechnology could be making a comeback.
http://sa.iguana2.com/cache/e2f83fe4...AVX-272632.pdf
__________________________________________________ _________________
Heres abit more about avexa from: http://www.avexa.com.au/corporate/overview
Avexa, formed in 2004, is an Australian drug-discovery company based in Melbourne, Victoria.
Avexa™s business is the discovery and development of anti-infective pharmaceutical medicines for the treatment of serious human infectious diseases.
Avexa™s principal research programs focus on the discovery of innovative medicines for the treatment of the diseases caused by:
Human Immunodeficiency Virus (HIV);
Vancomycin- and methicillin-resistant bacteria.
Each of these programs represents an area of significant medical need and high market potential and is designed to discover and develop innovative compounds which have a competitive edge.
-
Thanks Donnie... I'm convinced there's value out there in biotech at the moment...I'm just not sure where. Holding PTD and NLS at the moment on the ASX. Oh, and IBA - but I'd hardly count that as biotech! Anyway, thanks for all the posts.
-
Member
Evogenix slowly getting to $1 a nice confirmation announcement today.
EvoGenix Limited (ASX: EGX) today announced confirmation by collaboration partner
GlaxoSmithKline (GSK) of successful completion of the first project between the two companies.
Achievement of the target set for the project triggers a milestone payment to EvoGenix by
GSK. Financial terms were not disclosed.
Under the agreement, EvoGenix utilised its protein optimisation technology, EvoGeneTM, to
develop improved versions of a protein product from the GSK pharmaceutical pipeline. The
protein variants generated had improvements in affinity that exceeded the 20-fold goal
specified in the collaboration agreement.
EvoGenix announced completion of its work on the project in October last year. Subsequent
evaluation and confirmation of the results by GSK has now been finalized successfully. GSK will
be responsible for further development of the product, with EvoGenix eligible to receive
additional milestone payments as the product progresses through the pipeline. EvoGenix is
also set to earn royalties on product sales should it be approved and launched.
"The success of this project, under our first collaboration with a major pharmaceutical
company, demonstrates the ability of EvoGenix to deliver significant improvements in the
properties of therapeutic proteins for our partners. Such enhancements in potency and other
properties can make a key contribution to the eventual success of products when tested in
patients" commented Dr Rob Crombie, VP Business Development who was responsible for
brokering the original deal.
"We are delighted with this external validation of the success of the EvoGenix technology
platform” commented Dr George Kopsidas, Project Director and leader of the team of EvoGenix
scientists who worked on the project. “We look forward to similar success in our other
collaborative projects and in development of our internal portfolio of antibody drugs".
EvoGenix is employing its protein engineering technologies in developing a series of valuable
protein therapeutics internally, with a particular focus on antibody-based drugs, and also in
collaborations with companies such as GlaxoSmithKline, CSL Limited and Vegenics Limited.
About EvoGenix
EvoGenix Limited (ASX:EGX) has established leading technology capabilities for creating high
value antibody and protein-based therapeutics. The company exploits its capabilities through
technology collaborations with partner companies, and by development in-house of a
succession of wholly-owned antibody and protein products.
EvoGenix is progressively building company value by assembling a portfolio of revenues from
technology collaborations using its unique technology capabilities. Multi project
collaborations with GlaxoSmithKline and Australia’s CSL Limited have been announced in the
past 18 months as well as a recent single product agreement with Circadian Technologiesbacked
biotechnology company, Vegenics Limited.
At the same time EvoGenix is progressing its internal product pipeline, with current products
aimed at the treatment of osteoporosis, lung cancer, melanoma and respiratory infections.
Generally, these will be out-licensed prior to the clinical stage to meet the existing high
demand for new biotherapeutic products in the pharmaceutical industry.
-
Member
This deal should give the share price a jolt, after the long down trend its been on.
pSivida signs A$203 million (US$165 million)
Collaborative Research and Licensing Agreement
with Pfizer
Boston, MA. and Perth, Australia – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI), today
announced it has signed an exclusive worldwide Collaborative Research and License Agreement
with Pfizer Inc. (PFE: NYSE) for pSivida’s controlled drug delivery technologies, including the
MedidurTM technology, in ophthalmic applications.
Under the terms of the agreement, pSivida will receive up to A$191m (US$155m) in development
and sales related milestones. The two companies will work together on a joint research program
aimed at developing ophthalmic products using pSivida’s sustained drug delivery technology. In
addition to milestone payments, Pfizer will fund the cost of the joint research program. Pfizer will
have an exclusive license to market all products developed as part of this research collaboration in
ophthalmic applications and will pay pSivida a royalty on net sales of those products. Pfizer may
terminate the agreement on 60 days notice without cause.
In addition to the development and sales milestones and payment of the cost of the joint research
program, Pfizer has agreed to invest A$6.1m (US$5m) in ordinary shares of pSivida upon entering
into the License Agreement, the proceeds of which will be held in escrow until such proceeds can
be used (together with other cash available to pSivida) to redeem an outstanding convertible note.
If pSivida does not repay the full amount outstanding under the convertible note prior to June 4,
2007, Pfizer may elect during the 90 day period following June 9, 2007 to cause pSivida to return
the A$6.1m (US$5m) held in escrow, in which case the license agreement would terminate. Pfizer
has also agreed to invest an additional A$6.1m (US$5m) in pSivida common equity in the future,
subject to certain conditions.
“We believe this collaboration is another significant validation of the drug delivery systems that
pSivida has been developing since its founding,” said Dr. Paul Ashton, Managing Director, pSivida
Limited. “pSivida plans to pursue development and additional collaborations exploiting our
innovative drug delivery technologies in other parts of the body.”
Medidur™ is a tiny, injectable device designed for the sustained release
of drugs and is currently being studied for the treatment of Diabetic
Macular Edema (DME), the leading cause of blindness for Americans
under the age of 65. MedidurTM in combination with Fluocinolone
Acetonide is in Phase III clinical trials in DME in collaboration with
Alimera Sciences Inc., a specialty pharmaceutical company focused on
the ophthalmic industry.
-
Here's a useful biotech resource I just came across - has up to date summary information on many ASX listed biotechs. Interesting reading.
Valutech
-
Member
A good announcement out with the merger of peptech and evogenix.
thanks lizard for the link.
Peptech, EvoGenix merger to create giant
May 7, 2007 - 2:04PM
Drug maker Peptech Ltd is planning to merge with rival EvoGenix Ltd, in a $156 million deal.
It will create one of the biggest biotechnology companies in Australia and a major player on the world stage.
Peptech, a company with a market value of about $310 million, will acquire 100 per cent of the antibody therapeutics company in a cash and scrip deal worth $1.12 per share.
Peptech chief executive Dr John Chiplin, who will lead the new entity, said the merger will create a company "poised to be a major player on the world-wide antibody stage".
"What this gives us is a company of much bigger critical mass in the antibody sector, to compete effectively in the international market," Dr Chiplin said.
"EvoGenix and Peptech are an excellent strategic fit at all levels."
The offer, which has been recommended by EvoGenix directors and comprises 15 cents cash and 0.5055 Peptech shares, represents a 33 per cent premium to EvoGenix's price last Friday of 84.5 cents.
Shares in EvoGenix surged 19.53 per cent or 16.5 cents to $1.01 on Monday but Peptech fell 11 cents to $1.81.
Evogenix chief Dr Merilyn Sleigh, who will be retained in a senior advisory role, said the synergies between the two companies were too good to ignore.
"We've been working very hard to build value in the company both developing antibody products (and) pipelines ... and it's really clear to us that to develop the full value in our products we really need to be working within a better funded environment than we currently are," she said.
"This transaction is a fantastic opportunity for both EvoGenix and its shareholders to transfer those assets into the merged entity, to continue to share in the growth of those products and the upside of the future value."
The proposal follows speculation that Peptech could become a private equity target, after it was revealed the company had received a number of unsolicited approaches earlier in the year.
But speaking about the merger in Sydney, Dr Chiplin said the private equity approaches were "opportunistic" and no formal offers were ever made.
The EvoGenix merger had now trumped any likely takeover, Dr Chiplin said.
"We had these approaches just before the annual general meeting (in February)... but from Peptech management's perspective we weren't going to sit around just waiting or hoping to see if a bid would come in," he said.
"This is an example of Peptech getting on with our lives.
"The Peptech board consider the medium-term value that will be created by this merger to be the best course of action to drive significant shareholder value relative to other strategic options, which include private equity offers."
Intersuisse biotech industry analyst Dr Darren Grubb said the merger was a "very good" one from a strategic standpoint.
"To become a global antibody play, which Peptech is clearly becoming, they have to have a full suite of development and optimisation tools," he said.
"What this does is give Peptech a very powerful platform to commercially hone antibodies, which is what the market is looking for."
For EvoGenix he said it was a matter of "one-plus-one equals three", he said.
"It's really given EvoGenix's technology platform a bite to it," he said.
"In my view it is a very good deal for both shareholders."
The merger is subject to the approval of EvoGenix shareholders, with a tentative date of August pencilled in for a scheme meeting.
-
I thought it looked like a great merger and am disappointed at the strong negative reaction of the PTD share price.
Clearly EGX holders got a good deal at this point, since the merger values their human health portfolio considerably higher than Peptechs. Then again, they perhaps have more novel platforms (always difficult to value) - an area in which Peptech was weak. However, it would seem to me the synergies of the combined entity are more than enough to cover any premium paid for EGX. But, given market reaction, looks like I'll have to put these under the bed with all my other biotechs...
-
Member
CBB Cordlife has held up well since listing, it'll be interesting to see how it goes over the next few years.
Cordlife (CBB, formerly Cygenics Limited) is a biotechnology company focused on development and commercialisation of stem cell-related products, services, applications and technologies. Cordlife consists of tissue banking (Cord life Division), Consumable Products (Cell Sciences Division) and Cell Therapeutics and Technology Development (Cytomatrix Division).The company is part of a new international collaborative effort called PACRIMA, to develop new treatments for cancer. This will be done via the novel approach of developing and mobilising immune cells outside the human body.
Cordlife Division:
CordLife operates American Association of Blood Banks (AABB) compliant tissue banking facilities and provides tissue banking services in particular cord blood banking. The banking facilities comprise full processing and cryogenic storage capabilities.Formed CordLife Sciences (India) Private, a cord blood banking company, its head office in Kolkata.
Cell Sciences Division:
Cell Sciences designs, manufactures and markets proprietary range of disposable spinner vessels for use in attached and suspension cell culture, based on a patented 3-D growth scaffold. Products launched include three types of Cytomatrix scaffolds and two spinner based cell culture systems. Sales and distribution span over to the USA, Canada, Australia, EU South Korea, Thailand and China. Products were launched in 2004.Signed a Memorandum of Understanding with Rockeby Biomed for logistics, sales, marketing and master distribution of the Avian and Human Flu Tests.
Cytomatrix Division:
Cytomatrix was established in USA 1996, the division is built around a three-dimensional cell growth Matrix that enhances the growth of cells outside the human body. Cytomatrix operates mainly in stem cell expansion and T-cell production. Cytomatrix plans to further develop stem cell expansion through commercialisation of single use kits or license agreements. Cytomatrix is collaborating with clinical institutions and government agencies for T-cell research. Phase I/II human clinical trials are planned for Australia and Phase III human clinical trials will target Australia and USA.
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks